Study Regarding the Incidence of Anti-platelet Factor 4-antibodies in Patients Aged 18 to 60 Year… (NCT06650826) | Clinical Trial Compass
RecruitingNot Applicable
Study Regarding the Incidence of Anti-platelet Factor 4-antibodies in Patients Aged 18 to 60 Years With Spontaneous or Infection- or Vaccine-associated or Recurrent Venous and/or Arterial Thrombosis
Germany200 participantsStarted 2024-07-01
Plain-language summary
Prospective investigation of the incidence of anti-platelet factor 4 antibodies in suspected immune-associated arterial and/or venous thrombosis
Who can participate
Age range18 Years – 60 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Age between 18-60 years
* Written informed consent of the patient
* Spontaneous arterial and/or venous thrombosis
* infection-associated arterial and/or venous thrombosis within 30 days of infection
* Vaccine-associated arterial and/or venous thrombosis within 30 days of vaccination
* Recurrent arterial or venous thrombosis despite anticoagulant therapy
Exclusion Criteria:
* Lack of consent of the patient
* Risk-associated venous thromboses (e.g. following surgery, immobilization, plaster cast, fractures or sprains)
* Risk-associated arterial thromboses (in the presence of vascular risk factors such e.g. diabetes mellitus, hypercholesterolemia, hypertension, nicotine abuse)
* Thromboses more than 120 days old at the time of blood sampling
What they're measuring
1
Presence of anti-platelet factor 4 antibodies in temporal connection with the occurrence of arterial and/or venous thrombosis